Paul joined Venture Investors in 2006 as a Managing Director. Paul is focused on the firm’s therapeutics practice. Paul worked as a part-time Analyst for Venture Investors from 1989 to 1992 while receiving his MBA, and has been a member of the firm’s Investment Advisory Committee since 2001.
Paul serves on the Board of Directors of Aerpio Therapeutics (spun out of Akebia Therapeutics), Euthymics Bioscience, FluGen, Madison Vaccines, and Neurovance (spun out of Euthymics). He is a former board member of Akebia Therapeutics (NASDAQ:AKBA) and Tissue Regeneration Systems (now a Board Observer).
Paul has over 20 years of operating experience in the biotech and pharmaceutical industries. Previously, he served as President of the Gala Biotech business unit of Cardinal Health, a division that was established when the Venture Investors portfolio company, Gala Design, Inc., under his leadership was acquired. Prior to joining Gala, Paul served as Vice President of Business Development of 3-Dimensional Pharmaceuticals, a venture capital backed biotechnology company with a drug discovery platform that successfully completed an IPO during his tenure with the company, and was subsequently acquired by Johnson & Johnson. Prior to that, Paul worked as Director of Licensing for the pharmaceutical company Wyeth-Ayerst, which was a division of American Home Products (now part of Pfizer). Earlier, he served as Director of Business Development and Research for the Scientific Protein Labs (SPL) division of American Home Products. He began his career in industry as the Director of Operations of Columbia Research Labs.
In his spare time, Paul enjoys spending time with family (biking, swimming, and generally goofing off), learning more about wine (and hopefully not buying more!), cooking, and still playing softball and golf as time permits.